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Abstract
Accumulating data indicate that cancer stem cells contribute to tumor
chemoresistance and their persistence alters clinical outcome. Our previous study
has shown that ovarian cancer may be initiated by ovarian cancer initiating cells
(OCIC) characterized by surface antigen CD44 and c-KIT (CD117). It has been
experimentally demonstrated that a microRNA, namely miR-193a, targets c-KIT
mRNA for degradation and could play a crucial role in ovarian cancer development.
How miR-193a is regulated is poorly understood and the emerging picture is
complex. To unravel this complexity, we propose a mathematical model to explore
how estrogen-mediated up-regulation of another target of miR-193a, namely E2F6,
can attenuate the function of miR-193a in two ways, one through a competition of
E2F6 and c-KIT transcripts for miR-193a, and second by binding of E2F6 protein, in
association with a polycomb complex, to the promoter of miR-193a to down-
regulate its transcription. Our model predicts that this bimodal control increases the
expression of c-KITand that the second mode of epigenetic regulation is required to
generate a switching behavior in c-KIT and E2F6 expressions. Additional analysis
of the TCGA ovarian cancer dataset demonstrates that ovarian cancer patients with
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low expression of EZH2, a polycomb-group family protein, show positive correlation
between E2F6 and c-KIT. We conjecture that a simultaneous EZH2 inhibition and
anti-estrogen therapy can constitute an effective combined therapeutic strategy
against ovarian cancer.
Introduction
Ovarian cancer is the most lethal gynecological malignancy and the 5th leading
cause of cancer death among women [1]. As ovarian cancer has few symptoms
early in its course, the majority of patients are diagnosed with late stages (III and
IV) of the disease. The 5-year survival rate is generally less than 20% for patients
with advanced-stage disease despite therapeutic advances, whereas survival rate
for patients with stage I or II disease is greater than 80% for the same period [2].
Although current chemotherapeutics demonstrate a more than 90% complete
response rate in early-stage tumors, only a 20–30% partial response rate is
observed in advanced stage tumors as well as in chemo-resistant relapsed tumors
[3]. A better understanding of the molecular changes of ovarian carcinogenesis
may lead to better therapeutic strategies for this deadly disease.
An emerging hypothesis states that cancer arises from a small population of
self-renewing cancer initiating cells (CIC) [4]. These CICs are thought to possess
tumorigenic potential and enhanced drug resistance within a tumor, and are able
to repopulate tumor colonies in vivo. We have previously isolated ovarian CICs
(OCICs) from ovarian cancer patients [5]. These OCICs exhibit increased drug
resistance towards cisplatin and taxol, and are characterized by the expression of
several cell surface markers, including c-KIT (CD117, or stem cell factor receptor).
However, the mechanism of how OCICs arise and how these cell surface markers
are transcriptionally controlled are not fully understood.
Estrogen is an important regulator of growth and differentiation in normal
ovaries [6] and is involved in the development of ovarian cancer [7]. In this
regard, studies have explored the risk of ovarian cancer among women using
hormone replacement therapy (HRT) in the treatment of menopausal symptoms
[8, 9, 10]. For example, a study involving a million women suggested that women
treated with HRT were associated with an increased risk of ovarian cancer [11].
However, the role of estrogen in ovarian carcinogenesis is not fully understood.
Epigenetic modifications in the genome play a crucial role in transcriptional
control and aberrant epigenetic modification is now considered a hallmark of
cancer [12]. Epigenetic modifications are responsible for controlling gene
expressions that allow for specific phenotypes [13, 14]. Among them, DNA
methylation is one of the most characterized epigenetic modification which takes
place at the 59 position of cytosine in CpG dinucleotides resulting in the
formation of 5-methylcytosine. DNA methylation which occurs at the clusters of
CpG sites (called CpG islands) in the promoter region of a tumor suppressor gene
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results in transcriptional repression and tumorigenesis in some cases [15]. Also
considered as crucial regulators of gene expression, miRs are referred to as tumor
suppressor-miRs if they regulate the expression of an oncogene [14]. Studies
found that tumor suppressor-miRs are frequently down-regulated by genetic or
epigenetic mechanisms leading to the up-regulation of oncogenes and acceleration
of tumorigenesis [16]. For example, miR-34b/c (which resides at the promoter
CpG island of a gene) was found to be epigenetically silenced by DNA methylation
in metastatic cancer cells [17]. Re-expression of miR-34b/c suppressed cancer
invasion in vitro and in vivo.
We are interested in miR-193a which is located at chromosome 17q11.2 and
embedded in a CpG island. Studies have found that miR-193a was epigenetically
silenced by promoter hypermethylation in acute myeloid leukemia (AML) and
lung cancer [18, 19]. Importantly, miR-193a targets the stem cell marker, c-KIT,
for repression in AML [18, 20]. Another experimentally confirmed target of miR-
193a is E2F6 [21]. Up-regulation of E2F6 has been observed in breast cancer cells
upon treatment with estrogen [22]. Within the E2F family of transcription factors
which are involved in cell cycle control through transcriptional activation or
repression [23], E2F6 was found to be a transcriptional repressor capable of
associating with the histone-lysine N-methyltransferase EZH2, which is an
important constituent of the polycomb complex [24, 25], and with DNA methyl-
transferase DNMT3b, allowing for its recruitment to the repressive complex [26].
As the role of miR-193a in ovarian cancer is currently unknown, we
hypothesize that E2F6 protein may suppress the expression of miR-193a, both
directly as a DNA-binding transcriptional repressor and indirectly through
promotion of the polycomb complex assembly. Indeed, the existence of the
binding sites for E2F6 protein in the promoter of miR-193a as demonstrated by
ENCODE ChIP-Seq data [27] seems to suggest that long-term suppression of
miR-193a by E2F6 may lead to epigenetic silencing of miR-193a. These events
may lead to the up-regulation of c-KIT and trigger the onset of the OCIC
phenotype, thus promoting ovarian carcinogenesis. In this study, we use a
mathematical model to explore the intricacies of this epigenetic control of miR-
193a which could prove to be significant as it predicts a switching behavior in c-
KIT that could be critical for ovarian carcinogenesis.
Materials and Methods
Cell culture
Ovarian cancer cell line A2780 was propagated in RPMI1640 (Invitrogen,
Carlsbad, CA) supplemented with 10% FBS, and 50 units/ml of penicillin/
streptomycin. The cell was incubated at 37 C˚with 5% CO2.
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Cloning of miR-193a expressing vector
The sequences which transcribe miR-193a pre-miRNA was amplified by PCR
using specific primers F: 59-CGCGGATCCAGTTTCTCGGCGCATAACTC-39 and
R: 59-CCCAAGCTTCGCTATTTCTCCAGCGAAGTG-39, using genomic DNA of
IOSE cells which express miR-193a. The PCR products were ligated into yT&A
Cloning Vector (Yeastern Biotech, Taiwan) for sequencing confirmation. miR-
193a-yT&A was digested with BamH I and Hind III, and inserted into multiple
cloning site of pSilencer 4.1-CMV puro siRNA expression vector, which was
predigested with BamHI and HindIII.
Extraction of RNA and Quantitative RT-PCR
RNA extraction was performed using TRIzol reagent (Invitrogen Carlsbad, CA)
according to the manufacturer’s protocol. To remove potential contaminating
DNA from the complementary DNA, 1 mg of total RNA was treated with DNase I
(Amplification Grade, Invitrogen) prior to reverse transcription. RNA was then
reverse-transcribed using random primers (for c-KIT or E2F6 expression) or
TaqMan reverse transcription kit (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time RT-PCR was then performed using ABI StepOne real-time
PCR system (Applied Biosystems). Primers are available upon request. Relative
expression of miR-193a, c-KIT and E2F6 was calculated using the comparative Ct
method.
Results
miR-193a targets c-KIT and E2F6
To investigate the relationship between miR-193a and c-KIT/E2F6 in ovarian
cancer (Fig. 1A), we over-expressed miR-193a in A2780 ovarian cancer cells which
have low levels of miR-193a expression. Expression of miR-193a resulted in a
significant down-regulation of c-KIT mRNA and E2F6 mRNA, thus suggesting
that c-KIT mRNA and E2F6 mRNA are targets of miR-193a in ovarian cancer cells
(Fig. 1B).
Model equations
Interactions between the components of the miR-193a–E2F6–c-KIT regulatory
module are shown in Fig. 2A. Tight coupling of network components and
potential non-linear kinetics can give rise to complex system dynamics, which can
be understood with the help of a mathematical model. In our kinetic model
(Fig. 2B) there are six components, which represent: miR-193a (Rm), E2F6 mRNA
(Re), c-KIT mRNA (Rc), the complex of miR-193a with E2F6 mRNA (Rem),
complex of miR-193a with c-KIT mRNA (Rmc), and E2F6 protein (P). The
chemical mass-action equations for the respective concentration of these
molecules or complexes, Rm, Re, Rc, Rem, Rmc, and P, are stated as follows:
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dRm
dt
~
k4
1zK4P
zkm1Remzkm2Rmc{k1ReRm{k2RcRm{dmRm, ð1Þ
dRe
dt
~k5zkm1Rem{k1ReRm{deRe, ð2Þ
Fig. 1. miR-193a repress E2F6 and c-KIT. (A) Schematic diagram of c-KIT and E2F6 mRNA showing predicted miR-193a binding site at their 39UTR. The
detailed binding sequences (MREs) of these sites are also shown along with miRNA sequence alignments. (B) qPCR analysis of miR-193a, c-KITand E2F6
in A2780 ovarian cancer cells. Overexpression of miR-193a in A2780 cells leads to down-regulation of c-KIT and E2F6 mRNAs.
doi:10.1371/journal.pone.0116050.g001
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dRc
dt
~k6zkm2Rmc{k2RcRm{dcRc, ð3Þ
dRem
dt
~k1ReRm{km1Rem{demRem, ð4Þ
Fig. 2. The proposed miR-193a regulatory network. (A) Activation of estrogen receptor (ER) signaling may
increase the increase the transcription of E2F6 which may subsequently increase the expression of c-KIT
through miR-193a mediated ceRNA mechanism. On the other hand, in addition to transcriptional repressor,
E2F6 may lead to epigenetic silencing of the miR-193a promoter resulting in the up-regulation of c-KIT. The
description for each number in the pathway is listed in S1 Table. (B) The biochemical interaction for this
proposed miR-193a regulatory network. Model variables names for molecule species are also given.
doi:10.1371/journal.pone.0116050.g002
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dRmc
dt
~k2RcRm{km2Rmc{dmcRmc, ð5Þ
dP
dt
~k3Re{dpP: ð6Þ
Here, the association rate of miR-193a–E2F6 mRNA is k1 and association rate
of miR-193a–c-KIT mRNA is k2; the dissociation rate of complexes miR-193a–
E2F6 mRNA is km1 and miR-193a–c-KIT mRNA is km2; the translation rate of
E2F6 protein is k3; the transcription rate of miR-193a is k4, of E2F6 mRNA is k5
and of c-KIT mRNA is k6; the degradation rate of miR-193a is dm, of E2F6 mRNA
is de, of c-KIT mRNA is dc, of miR-193a–E2F6 mRNA is dem, and of miR-193a–c-
KIT mRNA is dmc and the degradation rate of E2F6 protein is dp; and the strength
of the miR-193a transcription inhibition by E2F6 protein is denoted as K4.
The first term on the right-hand side of Eq. (1) corresponds to arrow 9 in
Fig. 2A expressing miR-193a transcription inhibition by, primarily, E2F6 protein,
but also by polycomb complex proteins activity. The value of the parameter K4 is
thus intended to account for both the direct transcription repression by E2F6 and
for the long-term gene silencing performed by and dependent of the levels of
EZH2 and DNMT3b. (The concentration of E2F6 is a variable of the dynamical
model while levels of essential polycomb proteins, which are not explicitly present
in model equations, are not subjects to regulation by the module and their levels
are assumed constant at least at the module equilibration time scale.) The second
(respectively, third) term on the right-hand side of Eq. (1) is the rate of miR-193a
release from the complex with E2F6 mRNA (respectively, the complex with c-KIT
mRNA). Interactions corresponding to arrows 6 and 7 in Fig. 2A, expressing
hybrid mRNA complex formation, are given, respectively, by the fourth and the
fifth term on the right-hand side of Eq. (1). The last term in Eq. (1) is a first-order
miR-193a degradation term.
The rate of constitutive E2F6 gene transcription (arrow 1 in Fig. 2A) is k5 (Eq.
(2)). This rate depends on the level of hormonal stimulation and, as our model
describes simplified regulation in ovarian cells, we will directly associate k5 with
the level of estrogen. The second term in Eq. (2) represents the release of E2F6
mRNA from the complex with miR-193a, whereas the third term is the rate of the
opposite binding reaction. The last term in Eq. (2) is a degradation of E2F6
mRNA. The terms on the right-hand side of Eq. (3) are analogous. The first term
in Eq. (4) is the rate for the binding of E2F6 mRNA and miR-193a. The second
term in Eq. (4) stands for the opposite reaction, and the third term represents the
degradation of Rem. The terms on the right-hand side of Eq. (5) are analogous.
The last equation accounts for E2F6 translation (arrow 8 in Fig. 2A) and
degradation.
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Steady States
Steady states give the long-term behavior of the system. The steady states of
system (1)–(6) can be obtained by equating the right-hand sides of the equations
to zero. Let S5(Rm, Re, Rc, Rem, Rmc, P), be any steady state of system (1)–(6). The
steady state S satisfies the following equations
Re~
k5Ae
RmzdeAe
, ð7Þ
Rc~
k6Ac
RmzdcAc
, ð8Þ
Rem~
k1ReRm
km1zdem
, ð9Þ
Rmc~
k2RcRm
km2zdmc
, ð10Þ
P~
Mk5Ae
RmzdeAe
, ð11Þ
k4~h Rmð Þ, ð12Þ
where
Ae~
km1zdem
k1dem
, Ac~
km2zdmc
k2dmc
, M~
k3
dP
,
and
h Rmð Þ~ dmRmz k5RmRmzdeAez
k6Rm
RmzdcAc
 
Rmz dezK4k5Mð ÞAe
RmzdeAe
: ð13Þ
We note that once Rm is determined by Eq. (12), then the other components of
the steady state S can be determined by Eqs. (7)–(11). Hence the condition for the
existence of the steady state S is that k4 lies in h[0, ‘), the range of the function h.
We are interested in threshold or switching behavior of system (1)–(6),
particularly in switching of the expression of c-KIT mRNA. Thus, the conditions
on the parameters for the existence of multiple steady states are relevant. Here we
give a criterion for the existence of three steady states of the model as follows:
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k5zk6w
dmde km1zkemð Þ
k1dem
ð14Þ
dP
k3K4
vk5
km1zdem
k1dem
max
x§0
l xð Þ: ð15Þ
where max
x§0
l xð Þ is the maximal value of l xð Þ on the interval [0, ‘), and l xð Þ is given
by
l xð Þ :~ 1
xzdeAe
dmz
k5
xzdeAe
z
k6
xzdcAc
dmz
k5deAe
xzdeAeð Þ2z
k6dcAc
xzdcAcð Þ2
: x
xzdeAe
{1
0
@
1
A:
The proof for the criterion (14)–(15) is given in the S1 Text.
The Steady State Bifurcation Diagram in the (k5, Rc) plane
In view of Eqs. (7)–(8), the steady states of Re and Rc increase or decrease in the
same direction. This model prediction is consistent with the ceRNA hypothesis
[28, 29] that the expression of E2F6 positively correlates with that of c-KIT.
As mentioned before, k5 is an experimentally controllable parameter associated
with the addition of hormones (e.g., estrogen), and K4 is a measure of the
inhibition efficiency of, primarily, E2F6 protein against miR-193a. As we will see
in the discussion below, the interplay between k5 and K4 can generate an over-
expression of c-KIT mRNA. Hence, it would be interesting to see the dependence
of the steady state on the parameter k5 for different values of K4 – this is shown in
Fig. 3. This diagram is referred to as a ‘‘steady-state bifurcation diagrams’’, and k5
is referred to as a bifurcation parameter. To generate experimental curves similar
to those shown in Fig. 3, one can design an experiment in which cells are cultured
at different concentrations of estrogen, and then measure the long-term mRNA
levels.
With parameters satisfying Eq. (14)–(15), the model predicts that there is a
range of k5 for which the system admits three coexisting steady states. For
instance, for K450.0001 (i.e., a lower inhibition efficiency; Fig. 3, green line) and
k5 is between 0.0556 and 0.1585, the model gives three steady states (out of which
the high Rc and the low Rc states are stable; see the curve associated with
K450.0001 in Fig. 3). The importance of the right knee in a steady-state
bifurcation diagram lies in the following fact: as the control parameter k5 is
increased from the low value up through the critical value k5
R associated with the
right knee, the corresponding steady state level of Rc will increase and, due to the
instability (respectively, stability) of the steady states on the middle branch
(respectively, the upper branch) in the steady-state bifurcation diagram, the
system will jump to the steady state on the upper branch at the critical value k5
R,
Modeling Epigenetic Control of miR-193a
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and then stay on the upper branch (see Fig. 3). There is a sharp difference in c-
KIT mRNA levels between the steady states of Rc on the lower and upper branches
in the steady-state bifurcation diagram, which would suggest cancer phenotype-
promoting over-expression of c-KIT mRNA for k5.k5
R. On the other hand, if one
is initially at the steady state on the upper branch which is associated with the over
expression of c-KIT mRNA, one can decrease the k5 value to reduce the steady
state level of Rc. Moreover, if one continues to decrease the k5 value below the
critical value k5
Lassociated with the left knee, then the corresponding steady state
level of Rc will decrease and, due to the instability (respectively, stability) of the
steady states on the middle branch (respectively, the lower branch) in the steady-
state bifurcation diagram, the system will descend to the steady state on the lower
branch at the critical value k5
L (see Fig. 3). This would recover the normal c-KIT
mRNA level.
To summarize, the model predicts that there exists a threshold value k5
R
(respectively, k5
L) in the transcriptional rate k5 for cells to turn on (respectively,
turn off) the expression of OCIC marker c-KIT. Hence, it is important to adjust
the transcriptional rate k5 to affect the expression of OCIC marker c-KIT.
Significance of the Parameter K4
Although decreasing the value of k5 (associated with low estrogen level) can
reduce the expression of the OCIC marker c-KIT, some clinical evidence suggests
that anti-estrogen therapy is only partially effective in the treatment of ovarian
cancer [30, 31]. The model suggests that this might be due to the inhibition of
miR-193a expression by E2F6 protein as reflected in the value of the parameter K4
of the first term on the right-hand side of Eq. (1). This term is motivated by the
fact that the expression of miR-193a depends on the transcriptional suppressive
Fig. 3. Steady-state bifurcation diagrams. The dependence of the steady states of variable Rc (RNA level of
c-KIT) on parameter k5 (transcription rate of E2F6) for difference values of the parameter K4 (inhibition
efficiency of E2F6). The value of parameters are listed in S2 Text.
doi:10.1371/journal.pone.0116050.g003
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activity of E2F6 protein (associated with the level of EZH2 and DNMTs). In
particular, sufficiently strong inhibition (sufficiently large K4) would lead to a
more long-term silencing of the expression of miR-193a by DNA methylation (see
Eq. (1)), and thus would entail the over-expression of c-KIT mRNA; whereas for
the extreme case K450, the system (1)–(6) can only support at most one steady
state (see S1 Text), which implies the non-existence of the right and left knees in
the steady state diagram and loss of the bistable switch.
Let k5
b denote the basal transcription rate constant of E2F6 mRNA. In the
following, depending on the interplay between the k5
b and K4, we will describe two
scenarios in which the second one would correspond to the clinical observation
that anti-estrogen therapy are only partially effective in the treatment of ovarian
cancer [30, 31].
In cells with low inhibition efficiency of E2F6 (i.e., a lower K4), as the parameter
k5 is increased from k5
b to k5
2 (red solid line in Fig. 4A), the steady state of Rc will
first move from L0 to L1 via the lower branch, and, due to the instability of the
steady states in the middle branch, switch from L1 to U1 in the upper branch, and
finally move along the upper branch to U2. On the other hand, as the parameter k5
is decreased from k5
2 to k5
b (blue solid line in Fig. 4A), the steady state of Rc will
first move from U2 to U0 via the upper branch, and, due to the instability of the
steady states in the middle branch, then switch from U0 to T0 in the lower branch,
and finally move back to L0. Hence for low inhibition efficiency of E2F6 (i.e., low
K4) and small basal rate constant (i.e., small k5
b), addition of estrogen may turn
on over-expression of c-KIT mRNA, whereas retraction of estrogen can turn off
over-expression of c-KIT mRNA and make the cells recover the normal c-KIT
mRNA level.
In cells with high inhibition efficiency of E2F6 (i.e., a higher K4), as the
parameter k5 is increased from k5
b to k5
2 (red solid line in Fig. 4B), the steady state
of Rc will first move from L0 to L1 via the lower branch, and, due to the instability
of the steady states in the middle branch, switch from L1 to U1 in the upper
branch, and finally move along the upper branch to U2. On the other hand, as the
parameter k5 is decreased from k5
2 to k5
b (blue solid line in Fig. 4B), the steady
state of Rc will first move from U2 to U0 via the upper branch, and, due to the fact
that k5
b is the basal transcription rate constant of E2F6 mRNA and k5
b is larger
than the k5 component of left-knee point, then has to stop at U0 which is the state
associated with over-expression of c-KIT mRNA. Hence for high inhibition
efficiency of E2F6 (i.e., a higher K4) and large basal rate constant (i.e., large k5
b),
retraction of estrogen cannot attenuate the expression of c-KIT mRNA. We make
one important observation: for sufficiently large K4, the k5 value associated with
the left knee is very close to zero. Hence for sufficiently large K4, it would fit the
scenario discussed in this paragraph. This suggests that for sufficiently large K4,
retraction of estrogen cannot switch off over-expression of c-KIT mRNA, which is
consistent with the aforementioned clinical observation.
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Validation of the model in TCGA ovarian cancer dataset
In light of the above model, we reasoned that in ovarian cancer patients with low
EZH2 (i.e., low K4), increase of E2F6 mRNA (which results from an increase of
transcription rate of E2F6, k5) may induce the expression of c-KIT mRNA (Rc),
through miR-193a-mediated ceRNA mechanism. However, such correlation may
not exist in patients with high EZH2 (i.e., high inhibition constant of E2F6 to
miR-193a, K4) as miR-193 is epigenetically silenced. To provide an independent
support for this hypothesis, we analyzed the expression microarray data in TCGA
ovarian cancer dataset [32]. Interestingly, ovarian cancer patients with low EZH2
level show a positive correlation between the expression of E2F6 and c-KIT
(Fig. 5A). Analysis of another set of microarray data in ovarian cancer (GDS2785)
also demonstrated a similar phenomenon (S1 Fig.). However, such relationship is
not observed in patients with high EZH2 (Fig. 5B and S1 Fig.) or in the
Fig. 4. Steady-state bifurcation diagrams. The dependence of the steady states of variable Rc (RNA level of
c-KIT) on parameter k5 (transcription rate of E2F6) for different values of K4: (A) K450.1 (i.e., low inhibition
efficiency of E2F6), (B) K451 (i.e., high inhibition efficiency of E2F6). The red and blue arrow line indicates
abrupt shifts of the steady state of Rc with at different k5 values which indicated below. The value of
parameters are listed in S2 Text.
doi:10.1371/journal.pone.0116050.g004
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Fig. 5. Correlation between expression level of E2F6 and c-KIT in expression microarray dataset from
TCGA ovarian cancer patients. Expression microarray data from 568 ovarian cancer patients are sorted
according to the expression level of EZH2. The scatter plot demonstrates the correlation between expression
level of E2F6 and c-KIT in ovarian cancer patients with (A) low EZH2 (bottom 12.5%) and (B) high EZH2 (top
12.5%). The R and P-value of the Pearson correlation are shown. Interestingly, as predicted by our model,
patients with low EZH2 shows a positive correlation of E2F6 and c-KIT (A, R50.322, P,0.005). Such
correlation is not observed in patients with high EZH2 (B, R50.2148. P.0.05). However, patients with high
EZH2 can be further separated into 2 sub-groups based on the median value of c-KIT (high, red color; low,
blue color). Neither of these sub-groups demonstrates a positive correlation between E2F6 and c-KIT.
doi:10.1371/journal.pone.0116050.g005
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correlation between E2F6 and a non-miR-193a target (S2 Fig.). Taken together,
this phenomenon is consistent with our prediction (Fig. 3) that mRNA of E2F6
and c-KIT demonstrates a ceRNA relationship at low K4.
Discussion
Our mathematical model postulates the existence of a bimodal epigenetic control
of miR-193a in ovarian carcinogenesis. In cells with low inhibition efficiency of
E2F6, there is a ,linear relationship between transcription of E2F6 and c-KIT
mRNA, thus suggesting a ceRNA relationship between these 2 genes. In this
ceRNA hypothesis [28, 29], the 39UTRs of several mRNAs contain the miR-
binding element(s) (MRE) and therefore compete for binding with the miR.
Theoretically, a miR can be epigenetically controlled by both promoter
hypermethylation and its ceRNA in a bimodal fashion.
It is also noteworthy to point out that this ceRNA relationship is a reversible
event, such that retraction of estrogen which results in lower expression of E2F6,
may reduce the expression of c-KIT (Fig. 6, upper panel). Such phenomenon can
be observed in normal ovarian epithelial cells or ovarian cancer cells in which the
E2F6 inhibition efficiency is low. Indeed, components of transcriptional
repressors such as EZH2 which is required for transcriptional suppression of E2F6
is found to be low in normal ovarian cells and a sub-set of ovarian cancer [33, 34].
Fig. 6. Proposed model for ovarian carcinogenesis. Under the condition of low EZH2 and DNMT3b expression (upper panel, as indicated by light blue
and red color), E2F6 only leads to a minimal suppression of miR-193a (i.e., low K4) and the relationship between E2F6 and c-KIT exhibits a ceRNA
relationship. As a result, the amount of c-KIT in the ovarian cancer cells depends on the amount of estrogen (this information is mediated by the level of
E2F6). On the contrary, under the condition of high expression level of EZH2 and DNMT3b (lower panel, as indicated by dark blue and red color), E2F6
exerts a high inhibition efficiency (i.e., high K4). Slight increment of E2F6 results in the epigenetic silencing of miR-193a and subsequently an over-
expression of c-KIT. Without miR-193a, the cells may be ‘‘locked’’ in a high c-KIT state resulting in ovarian carcinogenesis.
doi:10.1371/journal.pone.0116050.g006
Modeling Epigenetic Control of miR-193a
PLOS ONE | DOI:10.1371/journal.pone.0116050 December 29, 2014 14 / 17
Importantly, this is also consistent with the clinical evidence that the expression of
E2F6 and c-KIT are correlated in ovarian cancer patients with low expression of
EZH2 but not in cases of high EZH2 expression.
However, in cells with high inhibition efficiency of E2F6, our model predicts a
highly non-linear relationship between expression of E2F6 and c-KIT. Under the
condition of low expression level of E2F6, there follows a ceRNA relationship
between E2F6 and c-KIT. However, at high expression of E2F6 together with high
expression of transcriptional repressor such as EZH2, E2F6 may lead to epigenetic
silencing of the expression of miR-193a through trimethylated H3K27 and DNA
methylation (Fig. 6, lower panel). Taken together, these mechanisms may lead to
a non-reversible expression of c-KIT and activation of the cell growth signaling in
ovarian cancer [35]. This prediction is also consistent with the previous findings
that high expression of EZH2 is associated with poor survival in ovarian cancer
patients [34]. Inhibition of the EZH2 activity together with anti-estrogen therapy
may therefore be effective against ovarian cancer.
In summary, due to the nonlinearities and non-intuitive dynamics of the
bimodal regulation of miR-193a, we developed a mathematical model that
predicts c-KIT switching behavior. Importantly, a positive correlation of E2F6 and
c-KIT is only observed in ovarian cancer patients with low EZH2 expression.
Combination treatment of EZH2 inhibitor together with anti-estrogen therapy
may be a novel strategy against ovarian cancer.
Supporting Information
S1 Fig. Correlation between expression level of E2F6 and c-KIT in expression
microarray dataset from ovarian cancer patients (GDS2785). Scatter plot shows
the correlation between expression level of E2F6 mRNA and c-KIT in ovarian
cancer patients with (A) low EZH2 (n516) or (B) high EZH2 (n517) according
to the median level of EZH2 expression. The R and P-value of the Pearson
correlation are also shown. Although not statistically significant, a more positive
correlation between expression of c-KIT and EZH2 were observed in patients with
low EZH2 (R50.3516, P50.0766) than that of patients with high EZH2
(R50.2938, P50.1729).
doi:10.1371/journal.pone.0116050.s001 (TIF)
S2 Fig. Correlation between expression level of E2F6 and CDK5 in expression
microarray dataset from TCGA ovarian cancer patients. To examine if the
observation in S1 Fig. is a random event, we analyzed the correlation between
expression level of E2F6 and CDK5, a non-miR-193a target in ovarian cancer
patients with (A) low EZH2 (bottom 12.5%) and (B) high EZH2 (top 12.5%) as
demonstrated in S1 Fig. Positive correlation is not observed in these 2 group of
patients (p.0.05).
doi:10.1371/journal.pone.0116050.s002 (TIF)
S1 Table. Description of biological functions of each interaction in Fig. 1A.
doi:10.1371/journal.pone.0116050.s003 (PDF)
Modeling Epigenetic Control of miR-193a
PLOS ONE | DOI:10.1371/journal.pone.0116050 December 29, 2014 15 / 17
S1 Text. The existence of steady states.
doi:10.1371/journal.pone.0116050.s004 (PDF)
S2 Text. The values of parameters in Fig. 3 and Fig. 4.
doi:10.1371/journal.pone.0116050.s005 (PDF)
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